Arch Biopartners Inc. (OTCMKTS:ACHFF) (CVE:ARCH) Stock Gains Momentum: Jumps 5%

Arch Biopartners Inc. (OTCMKTS:ACHFF) (CVE:ARCH) was up 5%, and the stock has gained 12% in a week. The company has announced that a scientific team headed by the University of Calgary’s Dr. Danniel Muruve and their partners have published articles in the Science Advances journal highlighting the mechanism of dipeptidase-1 action in acute kidney injury. Muruve is equally an Arch Chief Scientific Officer.

Market Stats

On Thursday, ACHFF stock gained 5.87% to $2.848 with more than 300 shares, compared to its average volume of 17.7K shares. The stock has moved within a range of $0.5770 – 0.5770 after opening trading at $0.5770.

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

The mechanism through which DPEP-1 modulates leukocytes recruitment (i.e., inflammation) towards the kidney after ischemia-reperfusion damage, which happens when there is reduced blood flow to the kidney, as shown in this pre-clinical trial. In patients having heart surgery or kidney transplant, ischemia-reperfusion damage is a prevalent cause of AKI.

The mode of action of the two DPEP-1 inhibitors, the Metablok (SALT peptide) and cilastatin, which efficiently safeguarded the kidney following ischemia-reperfusion injury, was also verified in the trial. Notably, both cilastatin and LSALT peptides are safeguarded by the method of sues and composition patents for AKI. So, investors should watch ACHFF in the coming days.

Traders Corner

ACHFF stock is above the 20-Day and 50-Day Moving averages of $2.71 and $2.75 respectively. The stock is trading in the neutral zone with the RSI at 53.